3D Medicines Inc. (HKG:1244)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.790
-0.010 (-0.26%)
At close: Mar 10, 2026
32.52%
Market Cap 930.01M
Revenue (ttm) 491.34M
Net Income (ttm) -184.64M
Shares Out 245.39M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 80,000
Average Volume 64,850
Open 3.600
Previous Close 3.800
Day's Range 3.590 - 3.880
52-Week Range 2.830 - 10.020
Beta 0.28
RSI 34.83
Earnings Date Mar 27, 2026

About 3D Medicines

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the People’s Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC; and in P... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 183
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1244
Full Company Profile

Financial Performance

In 2024, 3D Medicines's revenue was 445.65 million, a decrease of -29.81% compared to the previous year's 634.95 million. Losses were -182.66 million, -65.19% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.